Skip to content

Haemonetics HAE Free cash flow yield

Free cash flow yield at other companies

Abbott logo
AbbottABT
4.1%+1.2pp
TFX
TeleflexTFX
2.7%-0.5pp
Boston Scientific logo
Boston ScientificBSX
3.7%+1.7pp
Medtronic logo
MedtronicMDT
5.2%+0.4pp
LivaNova logo
LivaNovaLIVN
4.6%-2.2pp
ICU Medical logo
ICU MedicalICUI
2.9%-1.0pp

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Calculated from Haemonetics’s reported figures.

Based on trailing twelve months.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's free cash flow yield?
Haemonetics (HAE) reported free cash flow yield of 9.9% in Q1 2026.
How has Haemonetics's free cash flow yield changed year-over-year?
Haemonetics's free cash flow yield increased by 122.9% year-over-year, from 4.5% to 9.9%.
What is the long-term trend for Haemonetics's free cash flow yield?
Over 3 years (2021 to 2026), Haemonetics's free cash flow yield has grown at a 78.1% compound annual growth rate (CAGR), from 1.8% to 9.9%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.